ABSTRACT
Transcatheter pulmonary valve replacement has become an attractive alternative to surgical approach in patients with dysfunctional right ventricular outflow tract. However, in certain cases, an unfavorable anatomy might complicate optimal valve deployment and stability. Several techniques have been described to reshape the landing zone and allow proper implantation of the transcatheter valve. Among them, the hybrid approach has gained attention as an interesting method for off-pump pulmonary valve replacement in patients with dilated right ventricular outflow tract. But to date, there is no standardized method to resize and reshape the landing zone for the stented valve. Here, we describe a reproducible method based on simple geometric rules to allow adequate remodeling of the main pulmonary artery to the desired dimensions in a single attempt, followed by perventricular implantation of a Venus P-valve.
Subject(s)
Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Pulmonary Valve Insufficiency , Pulmonary Valve , Cardiac Catheterization , Humans , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/surgery , Pulmonary Valve/diagnostic imaging , Pulmonary Valve/surgery , Pulmonary Valve Insufficiency/diagnostic imaging , Pulmonary Valve Insufficiency/surgery , Treatment OutcomeABSTRACT
JUSTIFICATIVA E OBJETIVOS: Alguns autoanticorpos são associados com achados clínicos peculiares. Pacientes com artrite reumatoide (AR) podem apresentar autoanticorpo anti-RO. O objetivo deste estudo foi estudar a prevalência e associações clínicas do anticorpo anti-RO em pacientes com AR. MÉTODO: Foram estudados 385 pacientes diagnosticados com AR e que possuíam teste Elisa para anti-RO. Também foram analisadas informações referentes ao perfil do paciente, avaliação funcional, DAS-28, manifestações extra-articulares, função tireoidiana, perfil de autoanticorpos e de tratamento.RESULTADOS: A prevalência do anticorpo anti-RO foi de 8,31%. Não houve diferença significativa em relação ao sexo, HAQ, DAS-28, classificação funcional em pacientes com anti-RO positivo (p = ns). Pacientes com anti-RO apresentaram idade menor ao diagnóstico (p = 0,02). Em relação às manifestações extra-articulares, encontrou-se maior prevalência de lesões valvares cardíacas (p < 0,001) em pacientes com anticorpo anti-RO.Não foram encontradas diferenças significativas na análise de outras desordens extra-articulares, associação com hipotireoidismo,amiloidose, tratamentos indicados, presença de fator reumatoide (FR) e anticorpo antipeptídeo cíclico citrulinado (anti-CCP). CONCLUSÃO: Pacientes com AR que apresentam o anticorpo anti-RO tem um início de doença mais precoce. O anticorpoanti-RO é um fator de risco para o desenvolvimento de lesões valvares. Não foram encontradas relações do anti-RO com tireoidopatias, amiloidose secundária e escolha de tratamento.
BACKGROUND AND OBJECTIVES: Some auto antibodies are associated with peculiar clinical findings. Patients with rheumatoid arthritis (RA) may have anti-RO antibodies. The objective of this study was to investigate the prevalence and clinical associations of anti-RO antibodies in RA patients. METHOD: We studied 385 patients with RA for anti-RO by Elisa testing and for clinical profile, functional assessment, DAS-28, extra-articular manifestations, thyroid function, auto antibodies and treatment. RESULTS : The prevalence of anti-RO was 8.31%. There was no significant difference in sex distribution, HAQ, DAS-28,functional classification in patients with positive anti-RO (p = ns). Patients with anti-RO were younger at diagnosis (p = 0.02).Analyzing extra-articular disorders we found a greater prevalence of cardiac valve lesions (p < 0.001) in patients with anti-RO antibodies. No differences were found in other extra-articular manifestations, associated hypothyroidism, amyloidosis, treatment requirements, presence of rheumatoid factor (RF) and anti citrullinated protein antibodies (ACPA). CONCLUSION : RA patients with anti-RO have disease onset at earlier age. Anti-RO is a risk factor for the development of valve lesions. There is no association between this antibody and thyroid disease, amyloidosis and treatment needs.